NCT02162225

Brief Summary

The investigators hypothesize that increasing plasma nitrite using dietary nitrate will improve platelet function and red cell deformability and decrease MCHC in patients with sickle cell disease. The investigators will test this hypothesis through administration of daily intake of beetroot juice (Unbeetable - Performance Drink) to patients with sickle cell disease for 28 days. The investigators will evaluate the safety of daily beet root juice intake in patients with sickle cell disease. In addition, the investigators will measure MCHC, red cell deformability, and platelet function (activation and aggregation) in response to daily intake of beet root juice in this patient population.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2014

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 9, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 12, 2014

Completed
3 months until next milestone

Study Start

First participant enrolled

September 1, 2014

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2019

Completed
Last Updated

August 2, 2018

Status Verified

July 1, 2018

Enrollment Period

4.4 years

First QC Date

June 9, 2014

Last Update Submit

July 31, 2018

Conditions

Keywords

Erythrocyte DeformabilityPlatelet ActivationPlatelet AggregationNitriteSickle Cell AnemiaDiet Therapy

Outcome Measures

Primary Outcomes (1)

  • Total Number of Participants with Adverse Events as a Measure of Safety and Tolerability as a function of time

    Physical symptoms will be assessed either by telephone or in person

    up to 58 Days

Secondary Outcomes (2)

  • Changes in Red blood cell properties as a function of time

    Days 1, 14, 28

  • Changes in Platelet function as a function of time

    Days 1, 14, 28

Study Arms (1)

Beet Juice

EXPERIMENTAL

Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days. On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28.

Drug: beet juice (Unbeetable)

Interventions

Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days. On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28.

Beet Juice

Eligibility Criteria

Age19 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • diagnosis of sickle cell anemia (Hb S/S or Hb S/beta thal0)
  • no acute illness at the time of obtaining the study
  • willingness to adhere to the study preparatory procedures including drinking the beet juice product daily
  • willingness to give consent in order to participate

You may not qualify if:

  • less than 19 years in age or older than 65
  • smoke or chew tobacco
  • currently take medications that affect stomach pH
  • atrophic gastritis
  • hypo-or hyperthyroidism
  • Type I or II diabetes
  • history of gout, kidney stones or hypotension
  • pregnant
  • aversion to the study-related testing procedures
  • allergy, sensitivity or aversion to the study beetroot juice beverage
  • suffered an acute sickle cell episode (involving hospitalization or a visit to the emergency room) within the past six months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wake Forest University School of Medicine

Winston-Salem, North Carolina, 27157, United States

Location

MeSH Terms

Conditions

Anemia, Sickle Cell

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, CongenitalAnemia, HemolyticAnemiaHematologic DiseasesHemic and Lymphatic DiseasesHemoglobinopathiesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Natalia Dixon, MD

    Wake Forest University Health Sciences

    PRINCIPAL INVESTIGATOR
  • Daniel B Kim-Shapiro, PhD

    Wake Forest University

    STUDY DIRECTOR
0

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 9, 2014

First Posted

June 12, 2014

Study Start

September 1, 2014

Primary Completion

February 1, 2019

Study Completion

April 1, 2019

Last Updated

August 2, 2018

Record last verified: 2018-07

Locations